Adverse drug reactions to systemic antifungals. Prevention and management.
about
High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infectionsStrong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.Lipid-based amphotericin B for the treatment of fungal infections.Tinea capitis: an overview with emphasis on management.The use of intermittent itraconazole therapy for superficial mycotic infections: a review and update on the 'one week' approach.Antifungal pharmacodynamics: review of the literature and clinical applications.Genital mycotic infections in patients with diabetes.Topographic diversity of fungal and bacterial communities in human skin.Emerging azole antifungals.A metabolomic perspective of griseofulvin-induced liver injury in mice.New treatments for vulvovaginal candidiasisIn search of the holy grail of antifungal therapySurveillance for nosocomial infections and fever of unknown origin among adult hematology-oncology patients.Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity.Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.Pharmacotherapy of disseminated histoplasmosis in patients with AIDS.Nosocomial cerebral aspergillosis: a report of 3 cases.Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study.
P2860
Q28292927-ABC831A8-1BA7-4CB1-A841-298998022795Q28345157-9A3DD3A1-2F4A-4EA7-9CD8-F37D1B1E7560Q33604227-751CACBB-3E70-4044-8DCB-310107EC9D2AQ33670881-B33BAE14-724A-4841-AEBD-F6F3D74DB0A2Q33749026-A65D95D3-E72F-4EE4-90C6-FB1B96595301Q34083129-F730FC8C-C385-422F-B0C7-9AC0ADFEDCB8Q34349532-0D11D16A-72DE-4481-A6DD-2A5C189DE19AQ34734628-53EC46A7-40E2-411F-A6F8-6CA9C20C46E1Q36066009-CB8C16B2-F705-4388-9415-7BC5F49CB7CEQ36425634-C3383CA8-5E19-43D2-91CF-4A6E75832108Q36625081-27C88ACA-4C03-489F-9580-F7A0FE454B20Q36672181-2A841316-86EF-404E-B4DC-0B25AE84EDBFQ40581817-974FF416-8EF5-41AC-8693-B14CA2B9B6D8Q40582555-6CE52A3B-D6EE-4E1B-AB90-4789DCE971C6Q40677144-AA1CEED6-718D-4AA7-B0DE-27310D3067E1Q40709108-84989059-296F-493E-9703-BCA220F8C3BEQ41157109-F7A1FCA4-47E2-4240-827C-5E97AD966ECFQ47647056-F22D0484-1A97-4CDE-805B-C8B47A3AEB81
P2860
Adverse drug reactions to systemic antifungals. Prevention and management.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Adverse drug reactions to systemic antifungals. Prevention and management.
@ast
Adverse drug reactions to systemic antifungals. Prevention and management.
@en
type
label
Adverse drug reactions to systemic antifungals. Prevention and management.
@ast
Adverse drug reactions to systemic antifungals. Prevention and management.
@en
prefLabel
Adverse drug reactions to systemic antifungals. Prevention and management.
@ast
Adverse drug reactions to systemic antifungals. Prevention and management.
@en
P2093
P1433
P1476
Adverse drug reactions to systemic antifungals. Prevention and management.
@en
P2093
J R Perfect
M H Lindsay
P304
P356
10.2165/00002018-199207050-00003
P577
1992-09-01T00:00:00Z
P6179
1052216340